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 Growth factors (GFs) are powerful signaling molecules with the potential to drive regenerative strategies, including
bone repair and vascularization. However, GFs are typically delivered in soluble format at supraphysiological doses
because of rapid clearance and limited therapeutic impact. These high doses have serious side effects and are expen-
sive. Although it is well established that GF interactions with extracellular matrix proteins such as fibronectin control
GF presentation and activity, a translation-ready approach to unlocking GF potential has not been realized. We dem-
onstrate a simple, robust, and controlledmaterial-based approach to enhance the activity of GFs during tissuehealing.
Theunderlyingmechanism is basedon spontaneous fibrillar organizationof fibronectin drivenby adsorptiononto the
polymerpoly(ethyl acrylate). Fibrillar fibronectinon this polymer, butnot aglobular conformationobtainedoncontrol
polymers, promotes synergistic presentation of integrin-binding sites and bound bone morphogenetic protein 2
(BMP-2), which enhances mesenchymal stem cell osteogenesis in vitro and drives full regeneration of a nonhealing
bone defect in vivo at low GF concentrations. This simple and translatable technology could unlock the full regenera-
tive potential of GF therapies while improving safety and cost-effectiveness. http://adINTRODUCTION o
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ag.org/Growth factors (GFs) are potent biological signals that regulate cell
growth, stem cell differentiation, and tissue healing (1, 2). GFs are wide-
ly used in the clinic despite major problems associated with serious off-
target effects due to their required use at supraphysiological levels. These
high levels are needed because of the rapid GF breakdown and clear-
ance from target sites. For example, routine clinical delivery of bone
morphogenetic protein 2 (BMP-2) in spinal bone fusions involves the
incorporation of BMP-2 in a collagen sponge carrier at a concentration
of 1.5 mg/ml (3). However, serious respiratory, neurological, and in-
flammatory complications have been reported that eventually led the
U.S. Food and Drug Administration to issue a public health notification
of life-threatening complications (4).
Material-based strategies to direct stem cell–based tissue repair
focus mostly on controlling integrin adhesion receptor–related
signaling through alterations in surface chemistry, stiffness, and nano-
topography (5–12). These approaches have provided marked results,
most notably in the area of bone cell, osteoblast, and differentiation.
However, these materials are highly engineered, nonbiocompatible, or
very delicate, and thus, translation remains a hurdle. Furthermore,
these material-based approaches typically do not control GF binding
and activity. Therefore, materials that mimic and exploit GF interac-
tions with extracellular matrix (ECM) proteins such as fibronectin
(FN) may provide novel substrates for localized, low-dose delivery
with high potency (1).
Seminal work has demonstrated that FN contains domains for effec-
tive GF binding (13). However, when adsorbed onto synthetic materials,FN typically adopts a globular conformation that is suboptimal for
presentation of GF- and integrin-binding regions (13, 14). Alternative-
ly, engineered recombinant proteins including integrin-binding and
GF-sequestering domains from FN have been incorporated within a
fibrin matrix to bind BMP-2 and promote bone repair (15). However,
this strategy relies on recombinant protein technology of a fibrin
matrix and intricate engineering that increases costs and complexity
(16, 17). Other approaches used to increase the effect of GFs by
presenting them within material systems [for example, using bio-
polymers based on polyelectrolyte multilayers (18), heparin-binding
peptides that sequester cell-secreted heparin proteoglycans and GFs
(19), and mineral coatings used as templates that bind GFs (20, 21)]
are being explored, but these strategies typically involve high GF doses.
Here, we demonstrate a simple, robust, and translational approach
to present BMP-2 in synergy with the integrin-binding domain of FN.
To achieve this, we use a simple polymer coating that spontaneously
assembles FN molecules into biological networks (22). Processing of
the synthetic polymers to produce our coatings involves solvents, but
these are removed after the fabrication process (spin coating), and it is
envisaged that we can use non–solvent-based techniques such as plas-
ma polymerization. Here, we show that this material-driven FN fibril-
logenesis provides synergistic integrin/BMP-2 signaling that drives
osteoblastic differentiation in primary human mesenchymal stem cells
(MSCs) in vitro and fully repairs nonhealing bone defects in vivo. It is
critical to note that this is achieved at a ~300-fold lower GF dose than
with collagen sponge delivery.RESULTS
Material-driven FN networks facilitate GF binding with
enhanced activity
Plasma FN is a dimeric glycoprotein with two subunits (~220 kD)
linked by a single disulfide bond. Each subunit contains three types1 of 10
R E S EARCH ART I C L Eof repeating modules (types I, II, and III), which mediate interactions
with other FN molecules (FNI1–5 and FNIII1–2), other ECM compo-
nents, integrins (FNIII9–10), and GFs (FNIII12–14) (Fig. 1A) (23). Cells
primarily interact with FN via integrins, a family of transmembrane
cell adhesion receptors. Integrin-mediated adhesion is a complex pro-
cess that involves clustering into supramolecular complexes that con-
tain signaling molecules and association with the actin cytoskeleton
(24). We have previously shown that adsorption of individual FN mol-Llopis-Hernández et al. Sci. Adv. 2016; 2 : e1600188 26 August 2016ecules onto a particular surface chemistry [poly(ethyl acrylate) (PEA)]
induces exposure of self-assembly sites (FNI1–5) to drive FN assembly
at the material interface (Fig. 1B) (25). This process involves the
70-kD N-terminal fragment of FN, which is required in physiological,
cell-induced, FN fibrillogenesis (26), giving rise to material-driven FN
fibrillogenesis (Fig. 1B) (22). Poly(methyl acrylate) (PMA) is used as a
reference polymer on which FN is adsorbed and maintains a globular
conformation (Fig. 1B). PMA otherwise behaves similarly to PEA in o
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 Fig. 1. Fibril-based GF presentation. (A) FN contains three types of domains that promote integrin binding (III9–10), GF sequestration (III12–14), and FN-FN
interactions (I1–5). (B) FN adsorption results in an FN nanonetwork spontaneously assembled on the material surface of PEA but not on PMA, allowing us to
propose synergistic integrin/GF receptor signaling to directMSC differentiation in vitro and tissue healing in vivo. (C) FN organized into fibrils on PEA displays
higher availability of the GF-binding region (FNIII12–14) than FN adsorbed on PMA in a globular conformation (left). However, similar surface density of BMP-2
on FN-coated PEA and PMA occurs regardless of the organization and conformation of FN on both surfaces (center). Very low release of BMP-2 over 14 days
was observed using enzyme-linked immunosorbent assay (ELISA). (D) Atomic forcemicroscopy (AFM) images at differentmagnifications after the sequential
adsorption of FN (3 mg/ml) andBMP-2 (25 ng/ml) on PEA andPMA.No FN/BMP-2 interactionswere notedonPMA (only randomapposition of bothmolecules
on the surface), whereas on PEA fibrillar FN molecules contained globular aggregates that we proposed to be BMP-2. (E) AFM images of BMP-2 interacting
with single FNmolecules on PEA (top, phasemagnitude; bottom, heightmagnitude as indicated on the pictures), where a secondary antibody (Ab) bound to
a 15-nm gold nanoparticle was used to identify BMP-2 on FN. The Tukey-Kramer method was used with multiple-comparisons posttest analysis of variance
(ANOVA). Symbols show statistical significant differences with all the other conditions on PEA (*P 0.001). a.u., arbitrary unit.2 of 10
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 terms of surface wettability, stiffness, and total surface density of ad-
sorbed FN (22). We have previously shown that this phenomenon of
organization of FN on PEA depends on the concentration of the
solution from which FN adsorption takes place, and a minimum con-
centration of >10 mg/ml is needed to achieve a full interconnection of
FN on PEA; increasing the concentration of FN on PMA only results
in a higher density of globular molecules on the surface (27). In ad-
dition, the phenomenon is rapid and allows FN organization within a
time scale of ~1 min (28). Further, we have recently shown that the
combination of EA and MA in a random copolymer modulates the in-
terconnection of FN nanonetworks in dependence of the composition
of the system (29).
Antibody-based assays revealed that FN was adsorbed on PEA in a
conformation that favors the simultaneous availability of the GF-
binding domain (FNIII12–14) next to the integrin-binding region
(FNIII9–10) (Fig. 1C, left) (30). Note that this change in the structure
of FN occurs without the application of external force, a method
known to alter the exposure of cryptic type III domains (31). The total
surface density of BMP-2 on these two FN-coated surfaces, quantified
by ELISA, was similar for PEA and PMA (Fig. 1C, center), and BMP-
2 remained stably adsorbed on these surfaces as a function of time,
with less than 10% released after 14 days (Fig. 1C, right).
AFM examination showed that BMP-2 was preferentially adsorbed
on top of FN molecules on PEA, whereas on PMA the GF appeared
adsorbed over the polymer surface (Fig. 1D). Bare PEA and PMA
surfaces are shown in fig. S1, and BMP-2 molecules directly adsorbed
on PEA and PMA (without FN) are shown as individual globules in
fig. S2. Figure 1D includes molecular-scale AFM phase magnitude
images of individual BMP-2 molecules sequestered onto open FN di-
mers (32). The FN open conformation sequestration of BMP-2 mole-
cules was assessed using an anti–BMP-2 antibody and then a secondary
antibody labeled with a gold nanoparticle (Fig. 1E). Individual FN mol-
ecules on PEA were observed using phase magnitude, whereas the gold
nanoparticles were depicted using height magnitude. A high-resolution
AFM image of one of these FN molecules in an extended conforma-
tion adsorbed on PEAwith one gold nanoparticle per FN arm is shown
in Fig. 1E; the section shows a height profile of ~7 nm that is compatible
with the dimensions of the gold nanoparticles buried within the anti-
body cluster. These results demonstrate that FN adsorption onto PEA,
but not PMA, results in controlled binding and presentation of BMP-2
to the adsorbed FN molecules.
Synergistic integrin/GF signaling drives MSC osteogenesis
To test whether PEA-driven integrin/BMP-2 presentation drives
MSCs to osteoblast differentiation through a synergistic mechanism,
BMP-2 (25 ng/ml) was adsorbed onto FN-coated PEA surfaces. The
ability of the PEA-controlled FN presentation to drive paired integrin
and BMP receptor localization required to drive synergistic signaling
was examined using coimmunoprecipitation of integrin b1, which
forms part of the FN receptor (33), and the BMP-2 receptor, BMPRIa.
Colocalization was seen using an anti-BMPRIa antibody in denaturing
conditions as a band at 60 kD (Fig. 2A) and quantified using the con-
dition without BMP-2 as a reference. These receptor coassemblies
were reduced either on FN nanonetworks assembled on PEA without
any BMP-2 or if the GF-binding site of FN (FNIII12–14) had been pre-
viously blocked with a monoclonal antibody (P5F3) to prevent BMP-2
binding (Fig. 2A, left). This colocalization of integrin and GF receptors
could also be seen at an individual cell level using immuno-Llopis-Hernández et al. Sci. Adv. 2016; 2 : e1600188 26 August 2016fluorescence (Fig. 2A, right). Figure S3 shows that colocalization is
specific to integrin b1 and does not happen with integrin b5, another
potential FN receptor (23).
This receptor colocalization had clear effects on subsequent cell
signaling. We first examined mediators of canonical BMP-2 signaling,
the Smads (small mothers against decapentaplegic), after 45 min of
MSC adhesion. Smads 1, 5, and 8 are phosphorylated by BMPRIa
and then translocate into the nucleus to activate RUNX2 (runt-related
transcription factor 2; the osteogenic master transcription factor) (34).
Results showed that Smads 1 and 5 were significantly more phos-
phorylated in the active state, with synergistic BMP-2 presentation
on PEA (Fig. 2B). Blocking the GF-binding region of FN (FNIII12–14)
with the P5F3 antibody or adding no BMP-2 reversed pSmad 1 and 5
phosphorylation to control levels, confirming that enhanced Smad
signaling is due to synergistic BMP-2 presentation. To confirm this, im-
aging of Smads 1 and 5 (after 90 min of MSC adhesion) showed arge
up-regulation when BMP-2 was synergistically presented (Fig. 2D).
We next examined the phosphorylation of ERK 1/2 that is impli-
cated in noncanonical BMP signaling; we note that this is complicated
because ERK 1/2 is also involved in focal adhesion signaling (35, 36).
Phospho-ERK (pERK) 1/2 levels were significantly higher for MSCs
cultured on FN fibrils with BMP-2 sequestered and had increased
trend for MSCs exposed to BMP-2 as a soluble factor in the culture
medium at 25 ng/ml compared to no BMP-2 control (Fig. 2C). This
allows a number of hypotheses to be proposed—that ERK 1/2 is acti-
vated by noncanonical BMP-2 signaling, adhesion-related signaling, or
both pathways. Imaging showed that focal adhesion kinase (FAK) ex-
pression, which would drive ERK 1/2 phosphorylation in adhesion-
related signaling pathways, was unchanged for all conditions [Fig. 2D;
expression of phospho-FAK (pFAK) was negligible at this time point
as shown in fig. S4]. Again, pERK 1/2 expression was elevated with
both adsorbed and soluble BMP-2 (Fig. 2D), allowing us to propose
noncanonical BMP-2 activation of ERK 1/2. We note that previous
work has shown that there is no difference in adhesion size in MSCs
on PMA or PEA with FN adsorbed, again supporting that the ob-
served changes are driven by BMP-2 (37).
These results support the conclusion that enhanced canonical BMP-2
signaling is a consequence of the simultaneous occupancy of integrins
and BMP-2 receptors (34). Furthermore, the data suggest that this syn-
ergy is mediated by ERK 1/2 via a lesser degree of noncanonical BMP
signaling and that this ERK 1/2 mechanism may be more promiscuous
to both synergistic and soluble BMP-2 administration (Fig. 2E).
We next evaluated whether synergistic interactions between FN
and BMP-2 when immobilized on PEA modulate MSC osteogenesis.
We have noted that Smads and ERK 1/2 act to regulate RUNX2, and
Fig. 2D shows enhanced active phospho-RUNX2 (pRUNX2) expres-
sion in MSCs cultured on the synergistically presented BMP-2 environ-
ments compared to cultures using P5F3 or soluble BMP-2. These
differences in pRUNX2 may result in downstream effects on the ex-
pression of osteogenic proteins regulated by RUNX2 (38). qPCR results
for osteogenic markers and the corresponding immunofluorescence
images were measured after 14 days of MSC culture to capture early
stages of cell differentiation. Figure 2 shows that synergistic integrin/
BMP-2 presentation driven by PEA led to significantly higher osteocal-
cin and osteonectin expression at the transcription and protein levels
(Fig. 2, F and G). This system was significantly more effective than
soluble administration of the GF (BMP-2 medium; Fig. 2F). Also,
when the same experiments were done using PMA, where FN was3 of 10
R E S EARCH ART I C L Eadsorbed in a globular conformation, the level of cell differentiation
was low and insensitive to the route used to present the GF (Fig. 2F).
These results indicate that the presentation of BMP-2 in synergy
with the adhesion sites on FN on PEA is more effective at triggering
MSC osteoblastic differentiation compared to both the same concen-
tration of the GF on PMA and the soluble administration of the GF.
Figure 2H shows that bone-related ALP activity was higher when
BMP-2 was presented bound on FN on PEA compared to the soluble
administration. Figure 2H further demonstrates that blocking ofLlopis-Hernández et al. Sci. Adv. 2016; 2 : e1600188 26 August 2016BMP-2 with noggin reduced PEA-driven FN/BMP-2 osteogenic dif-
ferentiation, further implicating BMP-2 signaling.
Synergistic presentation of BMP-2 on material-driven FN
networks drives bone regeneration in a nonhealing defect
We evaluated the potential of the synergistic presentation of GFs and
adhesion sites on biomaterials in vivo using a murine nonhealing
radial bone defect model (39). This bone repair model has significant
advantages: (i) the 2.5-mm defect does not spontaneously heal, providing o
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 Fig. 2. Integrin/BMP-2 receptor cosignaling drives MSC osteogenesis. (A) Coimmunoprecipitation of integrin b1 and BMPRI occurred on BMP-2
sequestered by FN on PEA, and bands correspond to BMPRIa (60 kD) after precipitation with anti–integrin b1 antibodies. The graphs show quantification of
bands relative to the absence of BMP-2. This colocalization can also be seen in individual cellswith integrin b1 (stained red) andBMPRIa (stainedgreen). (B) Smad
signaling was drastically altered when BMP-2 was presented bound on FNIII12–14; blocking this GF-binding domain of FN (using the monoclonal antibody
P5F3 at a molar ratio of 1 with FN to block the GF-binding site) reduces Smad signaling. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (C) Phospho-
rylation of extracellular signal–related kinase (ERK) 1/2 was significantly enhanced on PEAwhen BMP-2 was presented at the material interface, sequestered
on FN, compared to thepresenceof the samedoses of the soluble factor. (D) In-cellWestern assay for Smad, FAK, pERK 1/2, andpRUNX2with BMP-2 on FNon
PEA, soluble BMP-2, and blocking with P5F3 before BMP-2 adsorption. (E) This fulfills the first part of the synergistic signaling hypothesis. (F) Quantitative
polymerase chain reaction (qPCR) for osteocalcin (OCN) and osteonectin (ON) after 14 days of culture (PEA and PMA); enhanced expression occurs when
BMP-2 was presented bound on FN compared to soluble administration of the GF or when BMP-2 was sequestered on the material surface (PMA) but not
bound to FN. (G) Immunofluorescence for osteocalcin and osteonectin confirmed the results obtained at the gene level [red, osteocalcin/osteonectin; blue,
4′,6-diamidino-2-phenylindole (DAPI)]. (H) Alkaline phosphatase (ALP) staining on PEA comparing BMP-2 bound to FN fibrils versus soluble BMP-2. Noggin
(50 ng/ml)was used in both conditions as the BMP-2 inhibitor to prevent activity (imagequantification included in thegraph). Results showmeans± SD [n=3
for all experiments, except for the graph in (H), where 9 imageswere used]. The Tukey-Kramermethodwas usedwithmultiple-comparisons posttest ANOVA.
Symbols show statistical significant differences with all the other conditions (*P = 0.001, ¥P = 0.01).4 of 10
R E S EARCH ART I C L Ea rigorous critical-size model; (ii) it allows for simple in vivo imaging
approaches [for example, Faxitron and microcomputed tomography
(mCT)]; and (iii) the ulna provides sufficient stabilization of the defect,
and no fixation plates and hardware are required, thereby simplifying
the surgical procedure and reducing the risk of infection, a major ad-
vantage over the rat calvaria and segmental femur defect models (39).
The implant consisted of polyimide sleeves (4 mm long; Fig. 3A)
coated with a thin layer of the PEA and PMA polymers (green fluo-
rescent dye in Fig. 3A). Then, either FN or FN/BMP-2 was adsorbed
on the cylindrical polymer surface. We used a very low concentrationLlopis-Hernández et al. Sci. Adv. 2016; 2 : e1600188 26 August 2016of BMP-2, which resulted in ~15 ng of BMP-2 on the wall of the
coated tubes (surface density of 100 ± 8 ng/cm2, as measured using
ELISA). This BMP-2 amount is still at least 50% lower than most ad-
vanced materials systems that have been tested in murine models
based on integrin-specific polyethylene glycol (PEG) hydrogels loaded
with BMP-2 (39). Note that even if humans and rodents do not
metabolize biologics at the same rate, the amount of BMP-2 we
used is ~300-fold lower than the clinical standard (3). The material
system is highly demanding because we intend to promote bone re-
generation of a nonhealing defect—a volumetric defect—by engineering o
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 Fig. 3. Bone regeneration in a critical-size defect with very low doses of BMP-2. (A) A cylindric polyimide sleeve was coated with the polymers
(either PEA or PMA; the figure shows a picture of the sleeve and the coating is shown with a florescent dye) and implanted in a critical-size defect
(2.5 mm) in a murine radius. Faxitron images show the evolution of the defect at different time points after implanting PEA coated with FN and BMP-2.
The total amount of BMP-2 was ~15 ng. (B) Three-dimensional (3D) mCT reconstructions for both PEA and PMA polymers after 4 and 8 weeks, with three
conditions: polymer only (PEA and PMA), FN coating on the polymer (FN), and FN coating on the polymer followed by BMP-2 adsorption (FN + BMP-2).
The positive control is a PEG hydrogel loaded with ~175 ng of BMP-2. (C) mCT measures of bone volume within the defects. (D) Sections of 8-week radial
samples stained with Safranin O/Fast Green. Arrow 1 shows the fibroblast-like morphology of cells. Arrows 2 and 3 show the new bone cells coming out of
both distal and proximal sides. Arrow 4 shows bone marrow–like cavities found in the new bone. Arrow 5 shows the point at the contact point of new
bone, coming out of both distal and proximal sides. Five animals (n = 5) per condition were used. Symbols show statistical significant differences with all
the other conditions (*P = 0.001).5 of 10
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 the material surface of a tube where this volume is contained. This is
fundamentally different from what has been done to date to promote
bone formation in vivo using engineered space-filling materials such as
hydrogels and porous scaffolds (39). We have included a PEG hydrogel
loaded with BMP-2 (75 mg/ml; ~175 ng within the defect) as a positive
control in Fig. 3. This represents more than 100 times the amount used
in our system to achieve a similar quantitative result (Fig. 3C).
We evaluated bone healing by radiography and mCT at 4 and 8 weeks
after implantation (Fig. 3, A and B).We examined three groups for each
of the coatings (PEA and PMA): (i) polymer only, (ii) polymer coated
with FN (20 mg/ml), and (iii) polymer coated with FN and BMP-2
(~15 ng). Results for mCT, including quantification of bone volume
(Fig. 3C), show that only when FN and BMP-2 were adsorbed on PEA
did the defect become fully repaired and bridged. Thus, the effect could
only be ascribed to the simultaneouspresenceof FNandBMP-2, promot-
ing enhancedactivity of theGF.The sleeve coatedwith eitherPEAonlyor
PEA + FN did not promote the same level of bone growth, although FN
did have some effect by itself with PEA (Fig. 3B). Also, this very low
amount of BMP-2 was not effective in promoting bone growth when
presented on PMA surfaces with FN (Fig. 3B). This result supports the
specificity of the synergistic integrin/GF receptor mechanism on PEA
shown in Fig. 2. Histological analysis at 8 weeks showed fibrous tissue
with no significant bone formation within the defect for all the con-
ditions except for PEA + FN + BMP-2, where bone formation and bone
marrow establishment in the center of the defect were noted (fig. S5).
Higher-magnification images within the defect confirm different tissue
architecture amongPEA, PEA+FN, and PEA+FN+BMP-2 (Fig. 3D).
Without BMP-2, cells are organized along a fibrillar ECMwith a fibro-
blastic morphology. However, on PEA + FN + BMP-2, cells are or-
ganized into cavity-like structures as in the bone marrow (arrows in
Fig. 3D). There is also a lack of bone marrow–related structures in the
cell organization observed on PEA+ FN (arrows). o
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The critical importance of protein structure in determining cell behav-
ior is known (40–42), but translating this strategy into clinically rele-
vant therapies has been challenging. Here, we describe a facile yet
robust engineering approach that allows reliable control of synergistic
integrin/GF signaling to promote stem cell differentiation and tissue
repair. Notably, PEA can be readily applied to diverse biomedical de-
vices, both planar and complex 3D geometries by spin coating, solvent
casting, and plasma polymerization (43). We demonstrate that FN nano-
networks, simply adsorbed onto PEA from a solution, allow for simul-
taneous availability of the integrin-binding region (FNIII9–10) and the
GF-binding region (FNIII12–13) (44) of this important ECM protein.
The FNIII12–14 region is classically described as the heparin-binding
region shown to be a promiscuous GF-binding region able to sequester
different GF families [for example, platelet-derived growth factor
(PDGF), fibroblast growth factor (FGF), and transforming growth
factor–b (TGF-b)] (13). As a proof of concept, we show here that
BMP-2 is bound onto the FN nanonetworks at the material interface,
and this binding/presentation promotes enhanced BMP-2 signaling in
MSCs, with very low doses of BMP-2 driving osteogenesis and complete
repair of nonhealing defects in vivo.We show, for the first time, a surface-
induced regeneration of the bone (volume) in a critical-size defect, em-
phasizing clinical potential. Previous studies have shown the importanceLlopis-Hernández et al. Sci. Adv. 2016; 2 : e1600188 26 August 2016of FN conformation in driving osteogenic differentiation on material
surfaces, with correct FN conformation required to allow enhanced avail-
ability of the integrin-binding site (41). Coating implants with FN
fragments leads to better osteointegration, which reveals the impor-
tance of integrin specificity–related mechanisms also in vivo (45).
Our results show a moderate effect for fibrillar FN nanonetwork pre-
sentation on PEA to induce osteogenesis both in vitro, as previously
reported (37), and in vivo (Fig. 3). This may be related to the presence
of GFs in the regenerative environment (medium/serum), which are
adsorbed on FN nanonetworks to induce synergistic signaling.
Other strategies to present GFs from a material surface, including
protein engineering techniques, the use of peptides that bind heparin
and then GFs (19), and the use of layer-by-layer technologies (16, 18),
have been shown to be more effective than the soluble administra-
tion of GFs but, critically, do not exploit synergy between GF and
integrin receptors to accelerate healing (1). The potential importance
of crosstalk between integrins and GFs was revealed in biological
sciences more than a decade ago (46) and was explicitly engineered into
a fibrin matrix using a recombinant fragment of FN consisting of
FNIII9–10/FNIII12–14 that promoted bone regeneration and wound
healing (15). More recently, it has been shown that matrix-bound
BMP-2 induced integrin-dependent Smad signaling, which helped
indicate that both receptors in synergy can potentiate each other to
increase control over cell fate (47). Note that this work only presented
BMP-2 from the material surface, and it was hypothesized that cell-
secreted FN was used to promote receptor crosstalk and simultaneous
integrin BMP receptor signaling. However, we have engineered the
cellular microenvironment to synergistically target integrins and GF
receptors with facile and translatable materials technology.
Currently, although widely used in the clinic (for example, bone
repair), the use of GFs has only been partially successful and even
controversial. Our polymer system has the potential to drastically
reduce GF dose and topically deliver the GFs to the site of regenerative
demand, maximizing the effects by targeting integrins and GF recep-
tors in synergy. Furthermore, the GFs remain bound and localized to
the material, and therefore, off-target effects should be reduced.MATERIALS AND METHODS
Preparation of materials and synergistic interfaces
Polymer sheets were obtained by radical polymerization of a solution
of the corresponding alkyl acrylate, that is, MA (methyl acrylate) and
EA (ethyl acrylate) (Sigma-Aldrich), using 1 and 0.35 weight percent
benzoin, respectively (98% pure; Scharlau), as a photoinitiator. The
polymerization was carried out up to limiting conversion. After polym-
erization, low–molecular mass substances were extracted from the ma-
terial by drying in vacuo to constant weight. Thin films were prepared
by using a spin coater (Brewer Science). To do that, PMA andPEAwere
dissolved in toluene at a concentration of 6 and 2.5%. Spin casting was
performed on glass coverslips at 2000 rpm for 30 s. Samples were dried
in vacuo at 60°C before their use. FN from human plasma (Sigma) was
adsorbed from solutions of 20 mg/ml for 1 hour at room temperature
(RT) and blocked in 1% bovine serum albumin (BSA) (Sigma)/Dulbecco’s
phosphate-buffered saline (DPBS) for 30 min at RT. For GF adsorption,
BMP-2 (25 ng/ml; R&D Systems, 355-BM or 355-BM/CF for AFM
studies) inDPBSwas used for 1 hour at RT. For AFM studies, FNwas
adsorbed from solutions of 3 mg/ml inDPBS. To observe the soleGF on6 of 10
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 the surface, 100 ng/ml was used as the concentration of BMP-2. For
synergy-blocking assays, FNIII12–14 domains were blocked before
BMP-2 coating using themonoclonal P5F3 antibody against this specific
region (Santa Cruz Biotechnology, sc-18827; 15 mg/ml). Finally, samples
were rinsed in DPBS to eliminate the nonadsorbed protein.
Atomic force microscopy
Experiments were performed using a multimode AFM equipped
with a NanoScope IIIA controller (Bruker) operating in tapping
mode; the NanoScope 5.30r2 software version was used. Si cantilevers
(Bruker) were used with a force constant of 2.8 N/m and a resonance
frequency of 75 kHz. The phase signal was set to 0 at a frequency 5
to 10% lower than the resonance one. Drive amplitude was 600 mV,
and the amplitude set point Asp was 1.8 V. The ratio between the am-
plitude set point and the free amplitude (Asp/A0) was kept equal to 0.8.
Immunogold staining
We used fixed samples (4% formaldehyde, 30 min at RT) with the dif-
ferent protein-coating conditions. Samples were incubated with an
anti–BMP-2/BMP-4 antibody (Santa Cruz Biotechnology, sc-9003;
1 hour at RT). After the samples were washed three times with
DPBS/0.5% Tween 20 in agitation, they were incubated with 15-nm
gold particle–conjugated anti-rabbit immunoglobulin G (IgG)
(Aurion, 815.011; 1 hour at RT). Finally, the samples were washed
and fixed (2% glutaraldehyde; 5 min at RT).
Availability of the FNIII12–14 domain
After coating with FN, a monoclonal antibody for the FNIII12–14
domain (also known as heparin II domain) was used (Santa Cruz
Biotechnology, sc-18827; 1:30, 2 hours at 37°C). Samples were
washed three times with DPBS/0.5% Tween 20. An anti-mouse
IgG horseradish peroxidase–conjugated antibody (Invitrogen,
626520; 1:2000, 1 hour at RT) was then used. After the samples were
washed twice, they were exposed to the substrate solution (R&D
Systems, DY999) and incubated for 20 min at RT in the dark. A stop
solution (R&D Systems, DY994) was added before the absorbance was
read at 450 nm.
Quantification of BMP-2 adsorption
Both on bare or FN-coated surfaces, the amount of nonadsorbed GF
that remained in the supernatant was measured via a sandwich ELISA
(R&D Systems, DY355) following the manufacturer’s instructions.
The standard curve was calculated using a 4PL curve fit (Prism).
For stability studies, the release of the BMP-2 was measured at 10 dif-
ferent time points (2 hours and 1, 2, 3, 4, 5, 6, 7, 11, and 14 days) using
the same sandwich ELISA.
Cell culture
Human bone marrow MSCs from PromoCell were maintained in ba-
sal medium [a-minimum essential medium, 10% fetal bovine serum
(FBS), 1% penicillin/streptomycin, 1% fungizone, 2 mM L-glutamine,
FGF-2 (1 ng/ml)] at 37°C with 5% CO2. Cells (10
4/cm2 ) were seeded
onto the materials using the seeding medium (high-glucose Dulbecco’s
modified Eagle’s medium, 1% penicillin/streptomycin, 1% FBS), and
the medium was changed twice a week. For all cultures, the first
2 hours (initial cell adhesion) were in the absence of serum and
GF. Cells were used at passages P0 to P3. Each experiment was
performed in triplicate.Llopis-Hernández et al. Sci. Adv. 2016; 2 : e1600188 26 August 2016Coimmunoprecipitation
After 45 min of cell culture, cell lysates [radioimmunoprecipitation as-
say (RIPA) buffer] were used to perform immunoprecipitation of integ-
rin b1 and the BMP-2 receptor BMPRIa. Proteins (15 mg) were
measured usingNanoDrop (ThermoFisher Scientific). First, an integrin
b1 antibody (Abcam, 183666; 10 ml per reaction) was used together
with Protein A-Agarose beads (Santa Cruz Biotechnology, sc-2001).
Second, after denaturation and elution of beads, the sampleswere run in
NuPAGE 4-12% bis-tris gels (Life Technologies). A mouse BMPRIa
antibody was used to probe themembrane (Abcam, 166707; 1:1000). An
anti-mouse secondary antibody was used (Santa Cruz Biotechnology,
sc-2031; 1:5000). The enhanced chemiluminescence detection system
(GE Healthcare) was used before the blot was exposed to x-ray.
ERK 1/2 phosphorylation
ERK 1/2 phosphorylation was quantified using phospho-ELISA kits.
Briefly, ELISA plates were coated with a capture antibody for ERK 1/2
and then incubated with cell lysates after 45 min of cell culture. Phos-
phorylated states were detected with an anti-phosphotyrosine anti-
body and normalized to a standard according to the manufacturer’s
instructions (R&D Systems, DYC1018B).
Immunofluorescence for BMPR and integrin colocalization
Cells were washed with 1× PBS and fixed with 4% formaldehyde so-
lution at 4°C for 15 min. Cells were then permeabilized with a solu-
tion of 0.5% Triton X-100 in PBS at 4°C for 5 min. A 1% BSA
solution was added, and the cells were incubated at 37°C for 5 min
to block nonspecific binding. After blocking, primary antibodies
[anti–integrin b1 (1:50; R&D Systems, MAB17781) and anti-BMPRIa
(1:50; Thermo Fisher Scientific, PA5-11856)] were added to the cells
and incubated at 37°C for 1 hour. Cells were then washed with 0.5%
Tween 20 in PBS (PBST) three times for 5 min each. Thereafter, a bio-
tinylated anti-rabbit secondary antibody (1:50; Vector Laboratories)
and a Texas Red anti-mouse secondary antibody (1:50; Vector Labora-
tories) were added to the cells and incubated at 37°C for 1 hour, fol-
lowed by 3 × 5% PBST washing. After washing, streptavidin–fluorescein
isothiocyanate was added and incubated at 4°C for 30 min. A final 3 ×
5% PBST wash was performed, and the nuclei of the cells were stained
using Vectashield-DAPI (Vector Laboratories), whereas the samples
were mounted on glass slides for fluorescence microscopy.
Smad phosphorylation
Cell lysates (RIPA buffer) were used after culture for 45 min. Proteins
(10 mg) were collected per sample. Western blot assays were run in
denaturalizing conditions for Smad 1, Smad 1/5, and GAPDH.
NuPAGE 4-12% bis-tris gels were purchased from Life Technologies.
pSmad antibodies (pSmad 1 and pSmad 1/5) were obtained from Cell
Signaling Technology (12656; 1:1000). As a secondary antibody, anti-
rabbit IgG antibody (Cell Signaling Technology, 7074; 1:2000) was
used. A substrate for sensitive immunodetection system (Life Technol-
ogies, Novex) was used before the blot was exposed to x-ray. Protein
expression was quantified by image analysis using ImageJ.
In-cell Western assay
Cells were fixed on coverslips using a fixative buffer (10 ml of form-
aldehyde, 90 ml of 1× PBS, and 2 g of sucrose) at 37°C for 15 min and
then permeabilized in cold methanol at 40°C for 5 min. Cells were
then blocked in 0.5% blocking buffer (nonfat dry milk powder in7 of 10
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 0.1% PBST buffer) at RT for 2 hours followed by 3 × 10-min washing
with 0.1% PBST. Cells were then incubated with primary antibodies at
1:200 dilution in blocking buffer at RT for 1.5 hours separately: Smad
1 (Cell Signaling, 6944S), Smad 5 (Cell Signaling, 12534S), pERK 1/2
(Cell Signaling, 4370S), ERK 1/2 (Cell Signaling, 4695S), pFAK (Cell
Signaling, 8556p), FAK (Cell Signaling, 13009P), and pRUNX2
(Abgent, AP3559a). After 3 × 10-min washing with 0.1% PBST
buffer, cells were incubated with 1:5000 diluted infrared-labeled
secondary antibody IRDye 800CW (LI-COR, 926-32211) and
1:2000 diluted CellTag 700 Stain ( LI-COR, 926-41090) at RT for
1 hour, followed by 5 × 10-min washing with 0.1% PBST. Glass
coverslips were then dried on white paper for infrared signal read-
ing using an Odyssey infrared imaging system.
Immunofluorescence staining for stem cell differentiation
After 14 days of culture, cells were washed in DPBS and fixed with 4%
formaldehyde in DPBS at 37°C for 15 min. Afterward, the samples
were rinsed in DPBS and a permeabilizing buffer [10.3 g of sucrose,
0.292 g of NaCl, 0.06 g of MgCl2, 0.476 g of Hepes buffer, 0.5 ml of
Triton X, in 100 ml of PBS (pH 7.2)] was added at 4°C for 5 min. The
samples were then saturated with 1% BSA/DPBS at 37°C for 5 min.
Subsequently, they were incubated at 37°C for 1 hour with a primary
antibody against osteocalcin (Santa Cruz Biotechnology, sc-73464;
1:50) or osteonectin (Santa Cruz Biotechnology, sc-10758; 1:50) in
1% BSA/DPBS. After washing in PBST, an anti-rabbit secondary
antibody (Vector Laboratories; 1:50) was incubated for 1 hour at
37°C. Finally, the samples were rinsed in DPBS before they were
mounted in Vectashield containing DAPI staining (Vector Labora-
tories). A Zeiss fluorescence microscope was used for imaging.
Quantitative real-time PCR
RNA extraction was performed after 14 days of cell culture. Cells were
lysed, and total RNA was extracted using a Qiagen RNeasy micro kit
(deoxyribonuclease treatment included), and the quantity and integri-
ty of the RNA were measured with NanoDrop (Thermo Fisher Scien-
tific). qPCR was carried out and analyzed to assess the expression of
osteocalcin and osteonectin using GAPDH to normalize gene expres-
sion (a list of the primers used is shown in table S1). Briefly, RNA
samples were reverse-transcribed using the QuantiTect Reverse
Transcription Kit (Applied Biosystems). qPCR was carried out using
the SYBR Select Master Mix (Life Technologies) and the 7500 Real-
Time PCR System (Applied Biosystems). GAPDH served as the
housekeeping gene, and the expression for the genes of interest was
normalized to the GAPDH expression. Because the SYBR Green
method was used, primer sequences for the genes were validated
by dissociation curve/melt curve analysis. The comparative cycle thresh-
old method was used for quantification of gene expression. The re-
lative transcript levels were expressed as means ± SD (n = 3 for
each group).
Alkaline phosphatase staining
Cells were cultured on materials for 28 days. Noggin (50 ng/ml) was
added in a set of samples, and phosphate deposition was analyzed by
an alkaline phosphatase assay (Sigma, 86C-1KT). Cells were fixed with
the fixative solution (citrate-acetone-formaldehyde solution) at RT for
30 s. Afterward, the samples were stained with the alkaline dye mix-
ture, incubated at RT in the dark for 15 min, counterstained for 2 min
with neutral red solution, and rinsed in tap water.Llopis-Hernández et al. Sci. Adv. 2016; 2 : e1600188 26 August 2016Implant preparation
Polyimide implant tubes presenting holes were coated by solvent
casting from solutions of the corresponding synthesized polymers,
PEA or PMA, creating a polymer layer on the tube. Implant tubes
were dried under vacuum at 60°C to remove solvent traces and were
rinsed with Milli-Q water several times before ultraviolet sterilization.
FN (Sigma) was adsorbed overnight on the polymer layer from a pro-
tein solution (20 mg/ml) in PBS at 37°C. Then, 1% BSA/PBS solution
was adsorbed for 30 min at RT to block nonspecific binding sites
before the adsorption of the BMP-2 GF (R&D Systems) from a solu-
tion (5 mg/ml) in PBS for 1 hour. The adsorption of the proteins was
performed by creating a vacuum to force the incoming of the solution
into the implant tubes. After each protein adsorption, the samples
were rinsed in PBS to remove the nonadsorbed protein and, finally,
were kept in PBS until implantation. GFOGER-functionalized PEG-
maleimide (PEG-MAL) hydrogels, which have been shown to pro-
mote osteogenic differentiation and bone healing of radial segmental
defects (39), were used as a positive control. Hydrogels were synthe-
sized by reacting the four-arm, MAL–end functionalized (>95%) PEG
macromer (PEG-MAL; 20 kD; Laysan Bio) with the adhesive peptide
GYGGGPG(GPP)5GFOGER(GPP)5GPC (GFOGER) (Activotec) and
BMP-2 (R&D Systems), followed by mixing with VPM cross-linker
(AAPTEC) at a volume ratio of 2:1:1:1. The final concentration of
the BMP-2 GF in the hydrogels was 75 mg/ml. The concentration of
VPM used was calculated to provide the same number of cysteine res-
idues than the number of free (unreacted) MAL groups remaining in
the adhesive peptide-functionalized PEG-MAL solution.
Bone radial segmental defect surgery
The Institutional Review Board and the Institutional Animal Care and
Use Committee guidelines were followed to perform in vivo
experiments. C57B1/6J male mice (8 to 10 weeks old; Jackson Labo-
ratory) were anesthetized under isoflurane, and the right forelimb was
shaved and swabbed with isopropyl alcohol and chlorhexidine. After
anesthesia induction, mice were provided with a single dose of sustained-
release buprenorphine for pain relief. An incision was made in the skin
along the forearm, and the muscle tissue over the radius was blunt-
dissected. A 2.5-mm defect was created in the center of the radius by
using a custom-made double-bladed bone cutter. The implant tube
was placed into the defect by fitting it at the proximal and distal ends
of the radial defect, and the incision was then closed with degradable
vicryl suture. The defect created was checked by the imaging with a
radiography system right after the surgery and before the recovery of
the animal. Mice were monitored after surgery for signs of distress,
movement, and weight loss.
Faxitron and mCT imaging
The radial defects were imaged with the MX-20 Radiography Equip-
ment (Faxitron; 23-kV energy and 15-s scan time) at different time
points: 0, 14, 28, 42, and 56 days. For mCT imaging, the length of the
radius (3.2 mm) centered on the 2.5-mm radial defect was scanned in
anesthetized live mice using a VivaCT system (ScancoMedical; 142-mA
intensity, 55-kVp energy, 300-ms integration time, and 15-mm reso-
lution) at 0, 4, and 8 weeks after surgery. Bone formation was eval-
uated by contouring 2D slices (including only the radius), which
were used to obtain 3D mCT reconstructions, displaying the total
length of the radius scanned. However, the quantification of the vol-
ume of new bone within the defect was performed by evaluating only8 of 10
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mation was measured.
Histology
At the end of the experiment (8 weeks), mice were euthanized and radial
bones were explanted, fixed in 10% neutral-buffered formalin solution,
decalcified (decalcifying solution; Ricca), and embedded in paraffin.
Sections (5 mm thick) were cut and deparaffinized before the Safranin
O/Fast Green staining. Samples were deparaffinized, rehydrated in water,
and incubated in Mayer’s hematoxylin solution for 10 min. After the
samples were rinsed in tap water, they were incubated in 0.5% Fast
Green solution for 10 s and rinsed in 1% acetic acid for 3 s. Finally,
the samples were incubated in 0.5% Safranin O for 2 min and then de-
hydrated and cleared in xylene before mounting them using DPX.
Statistical analysis
The Tukey-Kramer method was used with multiple-comparisons
posttest ANOVA.http://advances.science
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fig. S1. AFM height (left) and phase (right) images of bare PEA and PMA surfaces at different
magnifications from 500 nm to 5 mm.
fig. S2. AFM phase images of BMP-2 and PDGF-BB (100 ng/ml) adsorbed on PEA and PMA, with
indication of average size of the GF aggregates on each image.
fig. S3. Colocalization of integrin b5 and BMPRIa after 1 day of culture on PEA/FN/BMP-2.
fig. S4. Phosphorylation of FAK on PEA using different conditions for BMP-2 presentation: bound on
the surface as a coating versus soluble in the culture medium as well as using P5F3 control.
fig. S5. Full longitudinal sections of 8-week radial samples stained with Safranin O/Fast Green.
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